Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis.

Le Gall-Ianotto C, Le Calloch R, Couturier MA, Chauveau A, Lippert E, Carré JL, Misery L, Ianotto JC.

J Thromb Haemost. 2019 Jul 25. doi: 10.1111/jth.14588. [Epub ahead of print]

PMID:
31344312
2.

Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML Patients.

Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Réa D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX.

Clin Cancer Res. 2019 Jul 10. pii: clincanres.3373.2018. doi: 10.1158/1078-0432.CCR-18-3373. [Epub ahead of print]

PMID:
31292142
3.

A very potent factor V inhibitor interferes with the levels of all coagulation factors and causes a fatal hemorrhagic syndrome.

Hoffmann C, Amiral J, Rezig S, Kerspern H, Jantzem H, Robin S, Collins A, Mornet C, Mingant F, Pan Petesch B, Ianotto JC, Lippert E, Galinat H.

Eur J Haematol. 2019 Aug;103(2):137-139. doi: 10.1111/ejh.13249. Epub 2019 May 28.

PMID:
31102471
4.

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.

Ianotto JC, Curto-Garcia N, Lauermanova M, Radia D, Kiladjian JJ, Harrison CN.

Haematologica. 2019 Aug;104(8):1580-1588. doi: 10.3324/haematol.2018.200832. Epub 2019 Jan 24.

5.

What is pre-fibrotic myelofibrosis and how should it be managed in 2018?

Curto-Garcia N, Ianotto JC, Harrison CN.

Br J Haematol. 2018 Oct;183(1):23-34. doi: 10.1111/bjh.15562. Epub 2018 Oct 17. Review.

PMID:
30328618
6.

Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.

Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, Guièze R, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard M, Jourdan E, Vey N, Zerazhi H, Hishri Y, Mineur A, Asselineau J, Delepine R, Cahn JY, Ifrah N, Récher C; French Innovative Leukemia Organization.

J Clin Oncol. 2018 Sep 27:JCO2018787366. doi: 10.1200/JCO.2018.78.7366. [Epub ahead of print]

PMID:
30260758
7.

Statin exposure and thrombosis risk in patients with myeloproliferative neoplasms.

Delluc A, Lacut K, Pan-Petesch B, Galinat H, Lippert E, Ianotto JC.

Thromb Res. 2018 Jul;167:57-59. doi: 10.1016/j.thromres.2018.05.014. Epub 2018 May 16. No abstract available.

PMID:
29787944
8.

Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.

Mollard LM, Chauveau A, Boyer-Perrard F, Douet-Guilbert N, Houot R, Quintin-Roué I, Couturier MA, Dagorne A, Malou M, Le Calloch R, Luycx O, Thepot S, Hunault M, Guillerm G, Berthou C, Ugo V, Lippert É, Ianotto JC.

Leuk Lymphoma. 2018 Dec;59(12):2812-2820. doi: 10.1080/10428194.2018.1441408. Epub 2018 Apr 4.

PMID:
29616837
9.

Real-world incidence of cancer following a first unprovoked venous thrombosis: Results from the EPIGETBO study.

Delluc A, Ianotto JC, Tromeur C, De Moreuil C, Couturaud F, Lacut K, Le Moigne E, Louis P, Thereaux J, Metges JP, Mottier D.

Thromb Res. 2018 Apr;164:79-84. doi: 10.1016/j.thromres.2018.02.151. Epub 2018 Mar 2.

PMID:
29522910
10.

Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.

Le Clech L, Talarmin JP, Couturier MA, Ianotto JC, Nicol C, Le Calloch R, Dos Santos S, Hutin P, Tandé D, Cogulet V, Berthou C, Guillerm G.

Infect Dis (Lond). 2018 Jul;50(7):539-549. doi: 10.1080/23744235.2018.1438649. Epub 2018 Feb 16.

PMID:
29451055
11.

Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.

Mansier O, Luque Paz D, Ianotto JC, Le Bris Y, Chauveau A, Boyer F, Conejero C, Fitoussi O, Riou J, Adiko D, Touati M, Chauzeix J, Viallard JF, Béné MC, Giraudier S, Ugo V, Lippert E.

Am J Hematol. 2018 Aug;93(4):E84-E86. doi: 10.1002/ajh.25014. Epub 2018 Jan 12. No abstract available.

12.

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).

Le Calloch R, Lacut K, Le Gall-Ianotto C, Nowak E, Abiven M, Tempescul A, Dalbies F, Eveillard JR, Ugo V, Giraudier S, Guillerm G, Lippert E, Berthou C, Ianotto JC.

Haematologica. 2018 Apr;103(4):607-613. doi: 10.3324/haematol.2017.180448. Epub 2017 Dec 15.

13.

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ.

Haematologica. 2018 Mar;103(3):438-446. doi: 10.3324/haematol.2017.181297. Epub 2017 Dec 7.

14.

Incidence and impact of atrial arrhythmias on thrombotic events in MPNs.

Mahé K, Delluc A, Chauveau A, Castellant P, Mottier D, Dalbies F, Berthou C, Guillerm G, Lippert E, Ianotto JC.

Ann Hematol. 2018 Jan;97(1):101-107. doi: 10.1007/s00277-017-3164-x. Epub 2017 Nov 21.

PMID:
29164292
15.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
16.

Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms.

Perrier-Cornet A, Ianotto JC, Mingant F, Perrot M, Lippert E, Galinat H.

Platelets. 2018 Nov;29(7):723-728. doi: 10.1080/09537104.2017.1361018. Epub 2017 Nov 1.

PMID:
29090588
17.

Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, Guerci-Bresler A, Huguet F, Gardembas M, Escoffre M, Ianotto JC, Noël MP, Varet BR, Pagliardini T, Touitou I, Morisset S, Mahon FX; French Intergroup for Chronic Myeloid Leukemias.

Cancer. 2017 Nov 15;123(22):4403-4410. doi: 10.1002/cncr.30885. Epub 2017 Jul 25.

18.

Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms.

Ianotto JC, Couturier MA, Galinat H, Mottier D, Berthou C, Guillerm G, Lippert E, Delluc A.

Int J Hematol. 2017 Oct;106(4):517-521. doi: 10.1007/s12185-017-2282-5. Epub 2017 Jun 16.

PMID:
28623609
19.

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.

Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A.

Haematologica. 2017 Aug;102(8):1368-1377. doi: 10.3324/haematol.2017.165001. Epub 2017 May 18.

20.

The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes.

Le Clech L, Sakka M, Meskar A, Kerspern H, Eveillard JR, Berthou C, Buors C, Lippert E, Guillerm G, Quintin-Roué I, Carré JL, Ianotto JC.

Leuk Lymphoma. 2017 Nov;58(11):2582-2587. doi: 10.1080/10428194.2017.1312380. Epub 2017 May 9.

PMID:
28482711
21.

Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only.

Nicol C, Henry C, Couturier MA, Delépine P, Tripogney C, Buors C, Guillerm G, Berthou C, Tempescul A, Ianotto JC.

Leuk Lymphoma. 2017 Sep;58(9):1-3. doi: 10.1080/10428194.2017.1285025. Epub 2017 Feb 7. No abstract available.

PMID:
28278727
22.

Emergency Evacuation of Immunocompromised Patients From a Hematology Unit Following Flooding of High-Efficiency Particulate Air (HEPA) Filtration.

Saliou P, Ianotto JC, Couturier MA, Guillerm G, Le Bars H, Quinio D, Le Gal S, Baron R.

Infect Control Hosp Epidemiol. 2017 May;38(5):626-629. doi: 10.1017/ice.2017.18. Epub 2017 Feb 9. No abstract available.

PMID:
28179033
23.

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX.

J Clin Oncol. 2017 Jan 20;35(3):298-305. doi: 10.1200/JCO.2016.68.2914. Epub 2016 Oct 31.

PMID:
28095277
24.

Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.

Luque Paz D, Chauveau A, Boyer F, Buors C, Samaison L, Cottin L, Seegers V, Férec C, Le Maréchal C, Gueguen P, Lippert E, Ianotto JC, Ugo V.

Genes Chromosomes Cancer. 2017 May;56(5):354-362. doi: 10.1002/gcc.22437. Epub 2017 Feb 1.

PMID:
27997717
25.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX; France Intergroupe des Leucémies Myéloïdes Chroniques.

Blood. 2017 Feb 16;129(7):846-854. doi: 10.1182/blood-2016-09-742205. Epub 2016 Dec 8.

26.

Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus Rituximab: comparison between Deauville 5-point scale and International Harmonization Project criteria.

Lombion N, Robin P, Tempescul A, LE Roux PY, Schick U, Guillerm G, Ianotto JC, Berthou C, Salaün PY, Abgral R.

Q J Nucl Med Mol Imaging. 2016 Nov 30. [Epub ahead of print]

PMID:
27901328
27.

JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort.

Ianotto JC, Chauveau A, Mottier D, Ugo V, Berthou C, Lippert E, Delluc A.

Ann Hematol. 2017 Mar;96(3):383-386. doi: 10.1007/s00277-016-2853-1. Epub 2016 Oct 20.

PMID:
27766390
28.

External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis.

Astruc N, Ianotto JC, Metges JP, Lacut K, Delluc A.

Eur J Intern Med. 2016 Dec;36:e11-e12. doi: 10.1016/j.ejim.2016.08.001. Epub 2016 Aug 31. No abstract available.

PMID:
27592403
29.

Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study.

Orvain C, Luque Paz D, Dobo I, Cottin L, Le Calvez G, Chauveau A, Mercier M, Farhi J, Boyer F, Ianotto JC, Guibourg B, Rousselet MC, Zandecki M, Ifrah N, Hunault-Berger M, Ugo V, Genevieve F.

Ann Hematol. 2016 Oct;95(11):1819-23. doi: 10.1007/s00277-016-2784-x. Epub 2016 Sep 1.

PMID:
27582015
30.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.

31.

The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.

Laribi K, Tempescul A, Ghnaya H, Denizon N, Besançon A, Anghel A, Farhi J, Truong C, Lemaire P, Poulain S, Bolle D, Ianotto JC, Baugier de Materre A.

Hematol Oncol. 2017 Dec;35(4):536-541. doi: 10.1002/hon.2334. Epub 2016 Jul 22.

PMID:
27443419
32.

Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms.

Le Gall-Ianotto C, Brenaut E, Gouillou M, Lacut K, Nowak E, Tempescul A, Berthou C, Ugo V, Carré JL, Misery L, Ianotto JC.

Br J Dermatol. 2017 Jan;176(1):255-258. doi: 10.1111/bjd.14809. Epub 2016 Dec 22. No abstract available.

PMID:
27291777
33.

Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide.

Tempescul A, Ianotto JC, Bagacean C, Salaun PY, Bocsan C, Zdrenghea M.

Int J Hematol. 2016 Sep;104(3):400-2. doi: 10.1007/s12185-016-2020-4. Epub 2016 May 27.

PMID:
27233512
34.

Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance.

Gillet B, Ianotto JC, Mingant F, Didier R, Gilard M, Ugo V, Lippert E, Galinat H.

Thromb Res. 2016 Jun;142:26-32. doi: 10.1016/j.thromres.2016.04.006. Epub 2016 Apr 14.

PMID:
27105311
35.

[Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?].

de Moreuil C, Ianotto JC, Eveillard JR, Carrier M, Delluc A.

Rev Med Interne. 2016 Jul;37(7):473-9. doi: 10.1016/j.revmed.2015.12.025. Epub 2016 Jan 28. French.

PMID:
26833146
36.

Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 (V617F) and JAK2 exon 12 allele burden disappearance during the follow-up of two patients.

Mahé K, Luque Paz D, Couturier MA, Chauveau A, Quintin-Roué I, Berthou C, Ugo V, Lippert E, Ianotto JC.

Ann Hematol. 2016 Feb;95(3):529-31. doi: 10.1007/s00277-015-2559-9. Epub 2015 Nov 27. No abstract available.

PMID:
26611851
37.

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA.

J Clin Oncol. 2016 Jan 10;34(2):151-9. doi: 10.1200/JCO.2015.62.9337. Epub 2015 Nov 23.

38.

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ.

Blood. 2015 Dec 10;126(24):2585-91. doi: 10.1182/blood-2015-07-659060. Epub 2015 Oct 20.

39.

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

Martinaud C, Desterke C, Konopacki J, Vannucchi AM, Pieri L, Guglielmelli P, Dupriez B, Ianotto JC, Boutin L, Lataillade JJ, Le Bousse-Kerdilès MC.

Genom Data. 2015 Apr 29;5:1-2. doi: 10.1016/j.gdata.2015.04.017. eCollection 2015 Sep.

40.

Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.

Luque Paz D, Ianotto JC, Chauveau A, Guibourg B, Lecucq L, Lippert E, Ugo V.

Ann Hematol. 2016 Jan;95(2):349-50. doi: 10.1007/s00277-015-2518-5. Epub 2015 Oct 13. No abstract available.

PMID:
26459144
41.

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.

Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, Marzac C, Le Couédic JP, Droin N, Chachoua I, Favier R, Diop MK, Ugo V, Casadevall N, Debili N, Raslova H, Bellanné-Chantelot C, Constantinescu SN, Bluteau O, Plo I, Vainchenker W.

Blood. 2016 Jan 21;127(3):333-42. doi: 10.1182/blood-2015-07-661983. Epub 2015 Oct 8.

42.

Exudative pericarditis in the evolution of a diffuse large B-cell lymphoma.

Bagacean C, Tempescul A, Ianotto JC, Marion V, Pop D, Zdrenghea M.

Cardiovasc J Afr. 2015 Jul 23;26(4):e9-11. doi: 10.5830/CVJA-2015-024.

43.

Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis.

Martinaud C, Desterke C, Konopacki J, Pieri L, Torossian F, Golub R, Schmutz S, Anginot A, Guerton B, Rochet N, Albanese P, Henault E, Pierre-Louis O, Souraud JB, de Revel T, Dupriez B, Ianotto JC, Bourgeade MF, Vannucchi AM, Lataillade JJ, Le Bousse-Kerdilès MC.

Cancer Res. 2015 Nov 15;75(22):4753-65. doi: 10.1158/0008-5472.CAN-14-3696. Epub 2015 Sep 24.

44.

Encephalitozoon hellem in a patient with CD4+ T-cell prolymphocytic leukemia: case report and genomic identification.

Nevez G, Le Gal S, Quinio D, Ianotto JC, Berthou C, Hamane S, Sarfati C, Menotti J.

Diagn Microbiol Infect Dis. 2015 Nov;83(3):245-7. doi: 10.1016/j.diagmicrobio.2015.07.015. Epub 2015 Jul 26.

PMID:
26299583
45.

Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism.

Ianotto JC, Chauveau A, Luque Paz D, Delluc A, Tromeur C, Couturier MA, Gouillou M, Berthou C, Mottier D, Ugo V.

Thromb Haemost. 2016 Jan;115(1):225-6. doi: 10.1160/TH15-02-0134. Epub 2015 Aug 20. No abstract available.

PMID:
26290216
46.

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.

Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O.

Leukemia. 2015 Jan;29(1):249-52. doi: 10.1038/leu.2014.270. Epub 2014 Sep 12. No abstract available.

PMID:
25212275
47.

The arachidonic acid-LTB4-BLT2 pathway enhances human B-CLL aggressiveness.

Guriec N, Le Jossic-Corcos C, Simon B, Ianotto JC, Tempescul A, Dréano Y, Salaün JP, Berthou C, Corcos L.

Biochim Biophys Acta. 2014 Nov;1842(11):2096-105. doi: 10.1016/j.bbadis.2014.07.016. Epub 2014 Jul 26.

48.

Dissociated evolution of a multifocal primary CNS lymphoma.

Bagacean C, Zdrenghea M, Popescu C, Quintin-Roue I, Ianotto JC, Eveillard JR, Berthou C, Tempescul A.

J BUON. 2013 Oct-Dec;18(4):1098. No abstract available.

49.

Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.

Ghez D, Micol JB, Pasquier F, Auger N, Saada V, Spentchian M, Ianotto JC, Bourhis JH, Bennaceur-Griscelli A, Terré C, Castaigne S, Rigaudeau S, Rousselot P, de Botton S.

Eur J Cancer. 2013 Nov;49(17):3666-70. doi: 10.1016/j.ejca.2013.07.147. Epub 2013 Aug 19.

PMID:
23968731
50.

Fungal arthritis of the hip in patient with aplastic anaemia.

Le Calloch R, Ianotto JC, Guillerm G, Tonnelier JM.

BMJ Case Rep. 2013 Aug 13;2013. pii: bcr2013008902. doi: 10.1136/bcr-2013-008902.

Supplemental Content

Loading ...
Support Center